Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04935242
Other study ID # LAMA (LAbour Management)
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 19, 2021
Est. completion date April 26, 2022

Study information

Verified date April 2023
Source Groupe Hospitalier Paris Saint Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Syntocinon was granted marketing authorization in France in 1970. Since the 1960s, it has been frequently used during childbirth, particularly in cases of stagnation of cervical dilatation due to a lack of uterine contractility. According to the latest National Perinatal Survey of 2010, 66.5% of patients go into labor spontaneously and 58% of them receive Syntocinon during labor. The reported maternal effects associated with the use of synthetic oxytocin include uterine hyperactivity, postpartum hemorrhage (PPH) and severe PPH. The administration of oxytocin increases the risk of uterine hyperactivity in a dose-dependent manner. Regarding fetal risk, the reported adverse effects concern fetal heart rate abnormalities related to uterine hyperactivity. However, no study has shown an association between oxytocin administration and excess neonatal morbidity and mortality, except in the subpopulation of patients with a scarred uterus.


Description:

In the 1950s, the speed of cervical dilation during labor was studied by Friedman. Dilatation is then divided into several phases: - A first phase known as the latency phase which corresponds to the effacement of the cervix and its dilation up to 3 cm. It lasts on average 7 hours for a primipara and 5 hours for a multipara. - A second active phase which corresponds to the dilation of the effaced cervix. This phase includes the progressive acceleration phase (up to 4-5 cm of dilation), a phase of maximum slope (up to 9 cm) and a deceleration phase where the slope decreases from 9 cm to full dilation (FD). This active phase lasts, on average, 4h30 in primiparous women and 2h30 in multiparous women. Friedman concluded that cervical dilatation should be of the order of 1.5 cm/h and more in the active phase and that it should not fall below 1 cm/h in nulliparous women and 1.5 cm/h in multiparous women. In the 1980s, the use of syntocinon became commonplace.Under the influence of an Irish physician, O'Driscoll, policies of quasi-systematic direction of labor were implemented, in particular in nulliparous women. This concept of active management of labor was developed in response to the observation of a high rate of cesarean sections performed for stagnation. This active labor management included systematic rupture of membranes (amniotomy) and infusion of Syntocinon when the dilation rate was less than 1 cm/h. Beginning in the 2000s, Zhang also focused on the physiological duration of labor. He showed that a so-called normal labor could be much longer than previously described, especially before 6cm of cervical dilation. In 2010, he proposed a new partogram for nulliparous patients. Finally, Neal performed a review of the literature in 2010, evaluating 7,009 low risk primiparous patients in spontaneous labor. He showed longer active phase durations than those described so far. The duration of labor at the 95th percentile was 13.4 hours and the average dilation rate around 0.6cm/h. The author concludes that a dilation speed of 0.5 cm/h can be tolerated in primiparous patients, without requiring additional intervention. In this context, new French recommendations regarding oxytocin administration during spontaneous labor were published in December 2016. These recommendations were based mainly on studies including patients at term, without a history of cesarean section, with a single-fetal pregnancy and cephalic presentation: - It is recommended that the diagnosis of abnormal progression of labor (dynamic dystocia) not be made before 5-6 cm of cervical dilation, corresponding to the end of the latency phase of the 1st stage of labor (professional agreement). - It is recommended to consider a dilation speed as abnormal if it is less than 1 cm/4 h between 5 and 7 cm, and less than 1 cm/2 h beyond 7 cm of dilation (grade B) - In the absence of dynamic dystocia, active direction of labor is not recommended (Grade B) - Before 5 cm, it is recommended that neither amniotomy nor oxytocin administration be performed routinely, regardless of the speed of dilation (Grade B) - Early epidural analgesia (EAP) during the latent phase does not increase the frequency of indications for oxytocin administration during spontaneous labor (Grade B). - If dynamic dystocia is present during the active phase, amniotomy is recommended before oxytocin administration (professional agreement). - If the 2nd stage is prolonged beyond 2 hours, it is recommended that oxytocin be administered to correct a lack of progression of presentation (professional agreement) - It is recommended to start at an initial dose of 2 mIU/min (professional agreement). - Intervals of at least 30 min are recommended before each oxytocin dose increase (Grade B). - It is recommended that oxytocin be increased in dose increments of 2 mIU/min, not to exceed an absolute rate of 20 mIU/min, and that dose escalation be discontinued when cervical change or 5 uterine contractions per 10 min are achieved (professional consensus). These recommendations began to be applied in the maternity ward of Saint Joseph Hospital following their publication, starting in January 2017. These recommendations concern patients at low obstetrical risk, i.e., presenting a singleton pregnancy with a fetus estimated to be eutrophic and in cephalic presentation, a non-scarring uterus and spontaneous labor at term.


Recruitment information / eligibility

Status Completed
Enrollment 3311
Est. completion date April 26, 2022
Est. primary completion date September 19, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major patient - Single pregnancy - Non-scarring uterus - Fetus estimated to be eutrophic in prenatal - Cephalic presentation - Spontaneous labor from 37 weeks of amenorrhea Exclusion Criteria: - Patient under guardianship or curatorship - Patient deprived of liberty - Patient objecting to the use of her data for this research

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)

Lead Sponsor Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of professional practices before the recommendations for clinical practice (RPC) published in December 2016, concerning the modalities of administration of synthetic oxytocin during physiological labor Difference in management modalities between two groups of patients:
A first group of patients who gave birth in 2016
A second group of patients who gave birth in 2018
Day 1
Primary Assessment of professional practices after the recommendations for clinical practice (RPC) published in December 2016, concerning the modalities of administration of synthetic oxytocin during physiological labor Difference in management modalities between two groups of patients:
A first group of patients who gave birth in 2016
A second group of patients who gave birth in 2018
Day 1
Secondary Evaluation of the impact of the application of the new recommendations on the rate of vaginal deliveries Difference between these two groups of patients in terms of rate of vaginal delivery Day 1
Secondary Evaluation of the impact of the application of the new recommendations on the rate of postpartum hemorrhage Difference between these two groups of patients in terms of rate of postpartum hemorrhage Day 1
Secondary Evaluation of the impact of the application of the new recommendations on the rate of neonatal morbidity Difference between these two groups of patients in terms of rate of average APGAR scores in newborns measured at 1, 5 and 10 minutes of life Day 1
See also
  Status Clinical Trial Phase
Completed NCT02566356 - Adult Study Oxytocin - fMRI Early Phase 1
Completed NCT04330677 - Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin Phase 1
Completed NCT05827731 - Cervical Double Balloon Combined With Oxytocin N/A
Completed NCT02567032 - Adult Study Oxytocin - Behavioral Early Phase 1
Recruiting NCT04760496 - Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour Phase 4
Completed NCT03096249 - The Influence of Oxytocin on Socio-communicative Sensitivity Phase 1/Phase 2
Recruiting NCT05079841 - The Stimulation To Induce Mothers Study Phase 4
Completed NCT05059028 - Effect of Oxytocin Massage and Music on Breastfeeding N/A
Enrolling by invitation NCT06403982 - The Influence of Oxytocin on Intrapartum Fetal Well-being and Delivery Outcomes in Patients Receiving Epidural Analgesia N/A
Completed NCT03140709 - Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids N/A
Recruiting NCT04109339 - Effects of Oxytocin on Hemodynamics in Patients Undergoing Laparoscopic Myomectomy N/A
Completed NCT01891201 - Intrapartum Oxytocin Administration Affects Primitive Neonatal Reflexes N/A
Completed NCT05357521 - Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder
Completed NCT03140488 - Oxytocin Dosage to Decrease Induction Duration Phase 4
Completed NCT05823441 - Effect of Oxytocin Nasal Inhalation on Empathy Analgesia Phase 4
Not yet recruiting NCT06010368 - Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section Phase 3
Withdrawn NCT05608070 - IV Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy Phase 4
Completed NCT04441125 - The Effect of Labor Induction With Oxytocin on Early Postpartum Hemorrhage, Perineal Integrity and Breastfeeding
Recruiting NCT04551482 - Oxytocin for Weight Loss in Adolescents Phase 2
Completed NCT03255148 - Influence of Oxytocin on Resting State Neurophysiological Measures Phase 1